Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Urol
    August 2025
  1. LAZAROVICH A, Vigneswaran H, Palsdottir T, Eklund M, et al
    A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial: Erratum.
    J Urol. 2025;214:238.
    >> Share

    July 2025
  2. ERAKY A, Tilu N, Ben-David R, Hug B, et al
    Diagnostic Accuracy of [(18)F]-DCFPyL PSMA PET/CT in Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy: Is Pelvic Lymph Node Dissection Still Necessary?
    J Urol. 2025 Jul 7:101097JU0000000000004659. doi: 10.1097/JU.0000000000004659.
    >> Share

  3. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening: Erratum.
    J Urol. 2025;214:111.
    >> Share

    June 2025
  4. DOMINGO MR, Seibert TM
    Reply: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 20:101097JU0000000000004634. doi: 10.1097/JU.0000000000004634.
    >> Share

  5. FOGG RW, Krzastek SC, Vissichelli N, Defor E, et al
    Defining Abnormal Prostate Specific Antigen Values for Prostate Cancer Screening in the Spinal Cord Injury Population.
    J Urol. 2025 Jun 17:101097JU0000000000004644. doi: 10.1097/JU.0000000000004644.
    >> Share

  6. LUO H, Guo J, Li H, Su H, et al
    Letter: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.
    J Urol. 2025 Jun 10:101097JU0000000000004624. doi: 10.1097/JU.0000000000004624.
    >> Share

  7. KAPLAN-MARANS E
    Letter: Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging-Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
    J Urol. 2025 Jun 10:101097JU0000000000004625. doi: 10.1097/JU.0000000000004625.
    >> Share

  8. LEWICKI P, Borza T
    Editorial Comment: Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value.
    J Urol. 2025 Jun 4:101097JU0000000000004621. doi: 10.1097/JU.0000000000004621.
    >> Share

  9. WAGGENER K, Snipes M, Rais-Bahrami S
    Editorial Comment on: "Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer with Reliable Positive Predictive Value".
    J Urol. 2025 Jun 4:101097JU0000000000004620. doi: 10.1097/JU.0000000000004620.
    >> Share

  10. SANDLOW S, Carbunaru S, Sun Z, Ofori B, et al
    Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making.
    J Urol. 2025;213:713-721.
    >> Share

  11. SCUDERI S, Tin AL, Klug J, Porwal S, et al
    The Absolute Volume of Gleason Pattern 4 on Radical Prostatectomy Is More Strongly Associated With Advanced Stage and Biochemical Recurrence Than Gleason Grade Groups.
    J Urol. 2025;213:722-729.
    >> Share

    May 2025
  12. REESE AC
    Editorial Comment: Pelvic Lymph Node Dissection in Prostate Cancer-is It Really Necessary? A Multicentric Longitudinal Study Assessing Oncological Outcomes in Prostate Cancer Patients Undergoing Pelvic Lymph Node Dissection Vs Radical Prostatectomy On
    J Urol. 2025 May 23:101097JU0000000000004606. doi: 10.1097/JU.0000000000004606.
    >> Share

  13. DOMINGO MR, Do DD, Conlin CC, Bagrodia A, et al
    Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with reliable positive predictive value.
    J Urol. 2025 May 16:101097JU0000000000004611. doi: 10.1097/JU.0000000000004611.
    >> Share

  14. LAZAROVICH A, Vigneswaran H, Palsdottir T, Eklund M, et al
    A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial.
    J Urol. 2025;213:590-599.
    >> Share

  15. LI EV, Ren Y, Griffin J, Han J, et al
    An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial.
    J Urol. 2025;213:600-608.
    >> Share

  16. TOSOIAN JJ, Zhang Y, Meyers JI, Heaton S, et al
    Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine.
    J Urol. 2025;213:581-589.
    >> Share

  17. MANNAS MP, Deng FM, Ion-Margineanu A, Freudiger C, et al
    Stimulated Raman Histology and Artificial Intelligence Provide Near Real-Time Interpretation of Radical Prostatectomy Surgical Margins.
    J Urol. 2025;213:609-616.
    >> Share

    April 2025
  18. CHAPPIDI MR, Newcomb LF, Zheng Y, Liu M, et al
    Magnetic Resonance Imaging at second surveillance biopsy after diagnosis in patients with Grade Group 1 prostate cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2025 Apr 30:101097JU0000000000004592. doi: 10.1097/JU.0000000000004592.
    >> Share

  19. FURRER MA, Sathianathen NJ, Mulholland CJ, Papa N, et al
    Pelvic lymph node dissection in prostate cancer - is it really necessary? A multicentric longitudinal study assessing oncological outcomes in prostate cancer patients undergoing pelvic lymph node dissection vs radical prostatectomy only.
    J Urol. 2025 Apr 28:101097JU0000000000004587. doi: 10.1097/JU.0000000000004587.
    >> Share

  20. MARTIN SC, Gonzalez S, Kwan L, Delfin M, et al
    Evolution of Active Surveillance of Prostate Cancer: Impact of MRI, MRI-guided Biopsy and Focal Therapy.
    J Urol. 2025 Apr 21:101097JU0000000000004559. doi: 10.1097/JU.0000000000004559.
    >> Share

  21. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:538-540.
    >> Share

  22. BORDE T, Varble NA, Hazen LA, Saccenti L, et al
    Impact of Discordance Between Magnetic Resonance Imaging and Ultrasound Volume Measurements on Prostate Fusion Biopsy Outcomes.
    J Urol. 2025;213:428-436.
    >> Share

    March 2025
  23. NI X, Sui J, Wang B, Wang H, et al
    Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS.
    J Urol. 2025 Mar 25:101097JU0000000000004545. doi: 10.1097/JU.0000000000004545.
    >> Share

  24. ZHANG F, Li S
    Letter: A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004414. doi: 10.1097/JU.0000000000004414.
    >> Share

  25. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025 Mar 5:101097JU0000000000004491. doi: 10.1097/JU.0000000000004491.
    >> Share

    February 2025
  26. AHDOOT M, Naser-Tavakolian A, Heard JR, Williams C, et al
    PSA Density to Select MRI Targeted versus Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
    J Urol. 2025 Feb 14:101097JU0000000000004480. doi: 10.1097/JU.0000000000004480.
    >> Share

  27. MARRA G, Barletta F, Scuderi S, Montefusco G, et al
    Adjuvant radiation therapy or observation with or without early salvage radiation therapy for men with node positive prostate cancer after surgery and negative pre-operative conventional imaging: a multicenter study.
    J Urol. 2025 Feb 10:101097JU0000000000004468. doi: 10.1097/JU.0000000000004468.
    >> Share

  28. SHORE N
    Reply: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2025 Feb 10:101097JU0000000000004439. doi: 10.1097/JU.0000000000004439.
    >> Share


  29. Novel Intraprostatic Magnetic Resonance-Guided Implantation of Multidrug-Eluting Microdevice for Testing of Systemic Therapy Agents In Situ: Proof of Concept in Intermediate-Risk and High-Risk Prostate Cancer: Erratum.
    J Urol. 2025;213:266.
    >> Share

  30. LI EV, Bennett R 4th, Ho A, Wong C, et al
    Clinical Factors Associated With Suspicious (18)F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.
    J Urol. 2025;213:183-191.
    >> Share

  31. LENFANT L, Taille Y, Chartier-Kastler E, Lukacs B, et al
    Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France.
    J Urol. 2025;213:217-227.
    >> Share

    January 2025
  32. KIM EH, Jing H, Utt KL, Vetter JM, et al
    An Artificial Intelligence Model Using Diffusion Basis Spectrum Imaging Metrics Accurately Predicts Clinically Significant Prostate Cancer.
    J Urol. 2025 Jan 27:101097JU0000000000004456. doi: 10.1097/JU.0000000000004456.
    >> Share

  33. LUGHEZZANI G, Fasulo V, Lazzeri M
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2025 Jan 24:101097JU0000000000004420. doi: 10.1097/JU.0000000000004420.
    >> Share

  34. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:138-140.
    >> Share

    December 2024
  35. JONES JM, Matthew A, Tanguay S, Higano CS, et al
    A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2024 Dec 20:101097JU0000000000004359. doi: 10.1097/JU.0000000000004359.
    >> Share

  36. CANFIELD SE, George AK, Jue JS, Lewis SC, et al
    A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation.
    J Urol. 2024;212:862-872.
    >> Share

  37. FLEVILLE S, O'Neill C, Safar D, Macleod A, et al
    Diagnostic Pathway Outcomes for Biparametric Magnetic Resonance Imaging-Targeted Lesions Using Cognitive Registration and Freehand Transperineal Prostate Biopsy in Biopsy-Naive Men (CRAFT Single-Center Study).
    J Urol. 2024;212:821-831.
    >> Share

    November 2024
  38. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer.
    J Urol. 2024 Nov 15:101097JU0000000000004333. doi: 10.1097/JU.0000000000004333.
    >> Share

  39. NABI R, Zahid T, Farooqi HA
    Letter: Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Cente
    J Urol. 2024;212:762-763.
    >> Share

    October 2024
  40. FILON M, O'Neil B
    Can We Be Less Active in Prostate Cancer Surveillance?
    J Urol. 2024 Oct 16:101097JU0000000000004277. doi: 10.1097/JU.0000000000004277.
    >> Share

  41. FAKUNLE MO, Cowan JE, Washington SL 3rd, Shinohara K, et al
    Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2024 Oct 9:101097JU0000000000004265. doi: 10.1097/JU.0000000000004265.
    >> Share

  42. BHANJI Y, Mamawala MK, Fletcher SA, Landis P, et al
    Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging?
    J Urol. 2024 Oct 2:101097JU0000000000004268. doi: 10.1097/JU.0000000000004268.
    >> Share

  43. MA C
    Letter: Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:627-628.
    >> Share

  44. YAXLEY JW
    Letter: Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:628.
    >> Share

  45. CHOUDRY MM, Durant AM, Edmonds VS, Warren CJ, et al
    Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    J Urol. 2024;212:590-599.
    >> Share

    September 2024
  46. FLORES JM, Vertosick EA, Salter CA, Benfante N, et al
    Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004267. doi: 10.1097/JU.0000000000004267.
    >> Share

  47. STONE BV, Dominas CA, Bhagavatula SK, Ahn SW, et al
    Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004269. doi: 10.1097/JU.0000000000004269.
    >> Share

  48. CARLSSON SV, Carroll PR, Hamdy FC
    Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification.
    J Urol. 2024 Sep 17:101097JU0000000000004253. doi: 10.1097/JU.0000000000004253.
    >> Share

  49. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004239. doi: 10.1097/JU.0000000000004239.
    >> Share

  50. SHORE ND, De Giorgi U, Freedland SJ
    Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.
    J Urol. 2024 Sep 3:101097JU0000000000004228. doi: 10.1097/JU.0000000000004228.
    >> Share

  51. GAFFNEY CD, Vertosick EA, Laudone V, Goh AC, et al
    Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy.
    J Urol. 2024;212:401-408.
    >> Share

  52. KLOTZ L
    The Genomics and Natural History of MRI-Visible vs MRI-Invisible Prostate Cancers: Clinical Implications.
    J Urol. 2024;212:494-498.
    >> Share

  53. MIAN BM, Kaufman RP Jr, Berstein A, Fisher HAG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:511-512.
    >> Share

  54. DROGHETTI M, Ozman O, Berrens AC, Piazza P, et al
    Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:409-419.
    >> Share

  55. ZILLIOUX J, Camacho FT, Anderson RT, You W, et al
    Prevalence of Cognitive and Manual Dexterity Disorders Among Men Following Artificial Urinary Sphincter Placement.
    J Urol. 2024;212:441-450.
    >> Share

    August 2024
  56. SUN R, Shan D
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 23:101097JU0000000000004215. doi: 10.1097/JU.0000000000004215.
    >> Share

  57. BAHLER CD
    Reply: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Aug 12:101097JU0000000000004170. doi: 10.1097/JU.0000000000004170.
    >> Share

  58. SHORE N, Pieczonka C, Heron S, Gazi M, et al
    Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 9:101097JU0000000000004190. doi: 10.1097/JU.0000000000004190.
    >> Share

  59. NIU S, Ding X, Liu B, Ao L, et al
    Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prosp
    J Urol. 2024;212:280-289.
    >> Share

  60. VICKERS A, Vertosick E, Langsetmo L, Dahm P, et al
    Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.
    J Urol. 2024;212:310-319.
    >> Share

  61. SHORE N, Hafron J, Saltzstein D, Brown G, et al
    Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    J Urol. 2024 Aug 1:101097JU0000000000004163. doi: 10.1097/JU.0000000000004163.
    >> Share

    July 2024
  62. LENI R, Vickers AJ, Brasso K, Montorsi F, et al
    Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark.
    J Urol. 2024 Jul 31:101097JU0000000000004159. doi: 10.1097/JU.0000000000004159.
    >> Share

  63. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Letter: Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Jul 31:101097JU0000000000004171. doi: 10.1097/JU.0000000000004171.
    >> Share

  64. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    J Urol. 2024 Jul 30:101097JU0000000000004118. doi: 10.1097/JU.0000000000004118.
    >> Share

  65. ROY S, Sun Y, Chi KN, Ong M, et al
    Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial.
    J Urol. 2024 Jul 26:101097JU0000000000004158. doi: 10.1097/JU.0000000000004158.
    >> Share

  66. MAI Z, Yan W
    Letter: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Jul 25:101097JU0000000000004155. doi: 10.1097/JU.0000000000004155.
    >> Share

  67. GIESEN A, Devos G, Everaerts W, Joniau S, et al
    Letter: A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024 Jul 8:101097JU0000000000004127. doi: 10.1097/JU.0000000000004127.
    >> Share

  68. RIVIERE P, Deshler LN, Morgan KM, Qiao EM, et al
    PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening.
    J Urol. 2024 Jul 5:101097JU0000000000004138. doi: 10.1097/JU.0000000000004138.
    >> Share

  69. MOTA SM, Priester A, Shubert J, Bong J, et al
    Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
    J Urol. 2024;212:52-62.
    >> Share

  70. MIAN BM, Bernstein A, Kaufman RP Jr, Fisher HAG, et al
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:227-228.
    >> Share

  71. NAHAS WC, Rodrigues GJ, Rodrigues Goncalves FA, Sawczyn GV, et al
    Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:32-40.
    >> Share

  72. TILL C, Goodman PJ, Tangen C, Lucia MS, et al
    Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial.
    J Urol. 2024;212:228-229.
    >> Share

    June 2024
  73. NANDALUR KR, Shen C, Zhao L, Al-Katib S, et al
    Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2024 Jun 25:101097JU0000000000004117. doi: 10.1097/JU.0000000000004117.
    >> Share

  74. LEWICKI P, Morgan T
    The Genomics and Natural History of MRI Visible vs. Invisible Prostate Cancer: Clinical Implications".
    J Urol. 2024 Jun 12:101097JU0000000000004104. doi: 10.1097/JU.0000000000004104.
    >> Share

  75. MOSES RA, Hunter AE, Brandes ER, Zhang Z, et al
    Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
    J Urol. 2024;211:765-774.
    >> Share

  76. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:802-803.
    >> Share

  77. SZABO RJ
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:801-802.
    >> Share

    May 2024
  78. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    >> Share

  79. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    >> Share

  80. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    >> Share

  81. TRINH QD, Labban M, Daniels D, Feldman A, et al
    Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color.
    J Urol. 2024 May 4:101097JU0000000000003931. doi: 10.1097/JU.0000000000003931.
    >> Share

  82. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    >> Share

  83. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    >> Share

  84. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    >> Share

  85. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    >> Share

    April 2024
  86. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    >> Share

  87. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    >> Share

  88. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    >> Share

  89. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:623-624.
    >> Share

  90. CAKICI MC, Ozgur Kazan H, Yildirim A
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:624-625.
    >> Share

    March 2024
  91. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    >> Share

  92. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    >> Share

  93. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    >> Share

  94. HOUGEN HY, Sjoberg DD, Thomas J, Mahal BA, et al
    Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
    J Urol. 2024;211:392-399.
    >> Share

  95. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024;211:502-503.
    >> Share

    February 2024
  96. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    >> Share

  97. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    >> Share

  98. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    >> Share

  99. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
    Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
    J Urol. 2024;211:214-222.
    >> Share

  100. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:205-213.
    >> Share

  101. MISTRY NA, Sun Z, Sweis J, McCall C, et al
    Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
    J Urol. 2024;211:223-233.
    >> Share

  102. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
    Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
    J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
    >> Share

  103. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
    Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
    J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
    >> Share

    January 2024
  104. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
    >> Share

  105. GARNICK MB, Hafron J, Crawford ED
    Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.
    >> Share

    December 2023
  106. VAN NESTE L, Henao R, Wojno KJ, Signes J, et al
    Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
    J Urol. 2023 Dec 26:101097JU0000000000003824. doi: 10.1097/JU.0000000000003824.
    >> Share

  107. STIRA J, Gravina C, Lombardo R, De Nunzio C, et al
    Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone?Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Dec 22:101097JU0000000000003830. doi: 10.1097/JU.0000000000003830.
    >> Share

  108. REZAEE ME, Pallauf M, Fletcher SA, Han M, et al
    Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy.
    J Urol. 2023 Dec 18:101097JU0000000000003825. doi: 10.1097/JU.0000000000003825.
    >> Share

    November 2023
  109. TOSOIAN JJ, Yu A, Brisbane WG
    Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
    J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
    >> Share

  110. JOYCE DD, Filson CP, Herrel LA
    What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
    >> Share

  111. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
    Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
    J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
    >> Share

  112. LEPOR H
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
    J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
    >> Share

  113. CHEN Y, Liang Z, Yan W
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
    J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
    >> Share

  114. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
    Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
    J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
    >> Share

  115. SINGHAL U, Hollenbeck BK, Kaffenberger SD, Salami SS, et al
    Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice.
    J Urol. 2023;210:771-777.
    >> Share

    October 2023
  116. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
    Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
    >> Share

  117. TERAMOTO Y, Wang Y, Miyamoto H
    Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
    J Urol. 2023;210:639-648.
    >> Share

    September 2023
  118. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
    >> Share

  119. SHAH N, Ioffe V
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016